Jump back to 2021 and Neuren Pharmaceuticals Ltd (ASX: NEU) share price consistently traded around $1.50 and occasionally breached $2. Within three years it would hit a high of $25 a share. NEU received FDA approval for a drug called Trofenetide, a drug which treats a rare syndrome called Rett Syndrome. With a drug on the shelves in the US, NEU now has the cashflows to self-fund the next leg of growth.
We sit down with CEO, Jon Pilcher to discuss:
– The impact Trofenetide has on those who take it and their families
– The partnership and distribution model that brought Trofenetide to the US
– The life stages of a drug in development
– NEUs ability to self fund the development of a new drug – The company culture
– The timeframe and opportunity that lies ahead with NNZ-2591
– Thinking of share price movement and business performance separately
This conversation goes beyond investing and the numbers and talks about the lives impacted by NEUs work.
